UNLABELLED: The cblC defect is the most common inborn error of vitamin B12 metabolism. Despite therapeutic measures, the long-term outcome is often unsatisfactory. This retrospective multicentre study evaluates clinical, biochemical and genetic findings in 88 cblC patients. The questionnaire designed for the study evaluates clinical and biochemical features at both initial presentation and during follow up. Also the development of severity scores allows investigation of individual disease load, statistical evaluation of parameters between the different age of presentation groups, as well as a search for correlations between clinical endpoints and potential modifying factors. RESULTS: No major differences were found between neonatal and early onset patients so that these groups were combined as an infantile-onset group representing 88 % of all cases. Hypotonia, lethargy, feeding problems and developmental delay were predominant in this group, while late-onset patients frequently presented with psychiatric/behaviour problems and myelopathy. Plasma total homocysteine was higher and methionine lower in infantile-onset patients. Plasma methionine levels correlated with "overall impression" as judged by treating physicians. Physician's impression of patient's well-being correlated with assessed disease load. We confirmed the association between homozygosity for the c.271dupA mutation and infantile-onset but not between homozygosity for c.394C>T and late-onset. Patients were treated with parenteral hydroxocobalamin, betaine, folate/folinic acid and carnitine resulting in improvement of biochemical abnormalities, non-neurological signs and mortality. However the long-term neurological and ophthalmological outcome is not significantly influenced. In summary the survey points to the need for prospective studies in a large cohort using agreed treatment modalities and monitoring criteria.
UNLABELLED: The cblC defect is the most common inborn error of vitamin B12 metabolism. Despite therapeutic measures, the long-term outcome is often unsatisfactory. This retrospective multicentre study evaluates clinical, biochemical and genetic findings in 88 cblCpatients. The questionnaire designed for the study evaluates clinical and biochemical features at both initial presentation and during follow up. Also the development of severity scores allows investigation of individual disease load, statistical evaluation of parameters between the different age of presentation groups, as well as a search for correlations between clinical endpoints and potential modifying factors. RESULTS: No major differences were found between neonatal and early onset patients so that these groups were combined as an infantile-onset group representing 88 % of all cases. Hypotonia, lethargy, feeding problems and developmental delay were predominant in this group, while late-onset patients frequently presented with psychiatric/behaviour problems and myelopathy. Plasma total homocysteine was higher and methionine lower in infantile-onset patients. Plasma methionine levels correlated with "overall impression" as judged by treating physicians. Physician's impression of patient's well-being correlated with assessed disease load. We confirmed the association between homozygosity for the c.271dupA mutation and infantile-onset but not between homozygosity for c.394C>T and late-onset. Patients were treated with parenteral hydroxocobalamin, betaine, folate/folinic acid and carnitine resulting in improvement of biochemical abnormalities, non-neurological signs and mortality. However the long-term neurological and ophthalmological outcome is not significantly influenced. In summary the survey points to the need for prospective studies in a large cohort using agreed treatment modalities and monitoring criteria.
Authors: R Gutiérrez-Suárez; A Pistorio; A Cespedes Cruz; X Norambuena; B Flato; I Rumba; M Harjacek; S Nielsen; G Susic; D Mihaylova; C Huemer; J Melo-Gomes; B Andersson-Gare; Z Balogh; C De Cunto; R Vesely; K Pagava; A M Romicka; R Burgos-Vargas; A Martini; N Ruperto Journal: Rheumatology (Oxford) Date: 2006-07-28 Impact factor: 7.580
Authors: Sandra G Heil; Marije Hogeveen; Leo A J Kluijtmans; P J van Dijken; Gerard B van de Berg; Henk J Blom; Eva Morava Journal: J Inherit Metab Dis Date: 2007-09-04 Impact factor: 4.982
Authors: G A Mitchell; D Watkins; S B Melançon; D S Rosenblatt; G Geoffroy; J Orquin; M B Homsy; L Dallaire Journal: J Pediatr Date: 1986-03 Impact factor: 4.406
Authors: C Thauvin-Robinet; E Roze; G Couvreur; M-H Horellou; F Sedel; D Grabli; G Bruneteau; C Tonneti; A Masurel-Paulet; D Perennou; T Moreau; M Giroud; H Ogier de Baulny; S Giraudier; L Faivre Journal: J Neurol Neurosurg Psychiatry Date: 2008-02-01 Impact factor: 10.154
Authors: Gwendolyn Gramer; Junmin Fang-Hoffmann; Patrik Feyh; Glynis Klinke; Peter Monostori; Jürgen G Okun; Georg F Hoffmann Journal: World J Pediatr Date: 2018-06-15 Impact factor: 2.764
Authors: Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi Journal: Pediatr Nephrol Date: 2015-04-11 Impact factor: 3.714
Authors: Jens C Koenig; Frank Rutsch; Clemens Bockmeyer; Matthias Baumgartner; Bodo B Beck; Brigitta Kranz; Martin Konrad Journal: Pediatr Nephrol Date: 2015-04-18 Impact factor: 3.714
Authors: Mohammed Almannai; Ronit Marom; Kristian Divin; Fernando Scaglia; V Reid Sutton; William J Craigen; Brendan Lee; Lindsay C Burrage; Brett H Graham Journal: Mol Genet Metab Date: 2017-06-29 Impact factor: 4.797
Authors: Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman Journal: Invest Ophthalmol Vis Sci Date: 2015-12 Impact factor: 4.799